Diminished expression of complement regulatory proteins (CD55 and CD59) in lymphocytes from systemic lupus erythematosus patients with lymphopenia.
CD55 and CD59 are glycophosphatidylinositol-anchored proteins with complement inhibitory properties. Lymphopenia in systemic lupus erythematosus (SLE) has been associated with autoantibodies targeting nuclear antigens. The aim of this study was to evaluate the surface density of CD55 and CD59 in T and B lymphocytes from patients with SLE and lymphopenia and its possible correlation with the presence of common SLE autoantibodies. Flow cytometric analyses were performed on CD55 and CD59 stained CD3+ and CD19+ cells from 40 SLE patients, 30 with lymphopenia and 10 without it, and 25 healthy controls. Autoantibodies were detected in the sera by enzyme linked immunosorbent assay. The mean fluorescence intensity of CD55 and CD59 in T and B cells was significantly diminished in SLE patients with lymphopenia when compared with healthy subjects. Interestingly, the opposite was found in T and B cells from non-lymphopenic SLE patients. Although there was no correlation between CD55 and CD59 surface density and the presence of any specificity of the autoantibodies tested, higher titres of anti-dsDNA, anti-SM and anti-ribosomal p antibodies were significantly associated with lymphopenia. The deficiency of CD55 and CD59 expression may play a role in the pathophysiology of lymphopenia, most likely by increasing the susceptibility of cells to complement mediated cytolysis.
García-Valladares
I
I
Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Atisha-Fregoso
Y
Y
Richaud-Patin
Y
Y
Jakez-Ocampo
J
J
Soto-Vega
E
E
Elías-López
D
D
Carrillo-Maravilla
E
E
Cabiedes
J
J
Ruiz-Argüelles
A
A
Llorente
L
L
D000328:Adult; D000974:Antibodies, Antinuclear / Q000378:metabolism; D018941:Antigens, CD19 / Q000378:metabolism; D001402:B-Lymphocytes / Q000378:metabolism*; D017252:CD3 Complex / Q000378:metabolism; D018958:CD55 Antigens / Q000096:biosynthesis*; D018957:CD59 Antigens / Q000096:biosynthesis*; D016022:Case-Control Studies; D015536:Down-Regulation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000378:metabolism*; D008231:Lymphopenia / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D012698:Serologic Tests; D013601:T-Lymphocytes / Q000378:metabolism*
D000974:Antibodies, Antinuclear; D018941:Antigens, CD19; D017252:CD3 Complex; D018958:CD55 Antigens; D018957:CD59 Antigens